What is the primary indication for ezetimibe therapy?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

What is the primary indication for ezetimibe therapy?

Ezetimibe is used primarily to enhance LDL-C lowering when added to a statin, or as monotherapy in patients who cannot tolerate statins. It works by inhibiting the NPC1L1 cholesterol transporter on enterocytes in the intestine, which reduces the absorption of dietary and biliary cholesterol. This mechanism lowers the amount of cholesterol entering the bloodstream, complementing the statin’s reduction of hepatic cholesterol synthesis. The idea of increasing cholesterol excretion via bile describes what bile acid sequestrants do—they trap bile acids in the gut and force more cholesterol to be excreted in the stool, not ezetimibe’s action. Ezetimibe does not inhibit HMG-CoA reductase (that’s how statins work) and is not a primary treatment for severe hypertriglyceridemia.

Ezetimibe is used primarily to enhance LDL-C lowering when added to a statin, or as monotherapy in patients who cannot tolerate statins. It works by inhibiting the NPC1L1 cholesterol transporter on enterocytes in the intestine, which reduces the absorption of dietary and biliary cholesterol. This mechanism lowers the amount of cholesterol entering the bloodstream, complementing the statin’s reduction of hepatic cholesterol synthesis.

The idea of increasing cholesterol excretion via bile describes what bile acid sequestrants do—they trap bile acids in the gut and force more cholesterol to be excreted in the stool, not ezetimibe’s action. Ezetimibe does not inhibit HMG-CoA reductase (that’s how statins work) and is not a primary treatment for severe hypertriglyceridemia.

More practice questions